

# Lipocine to Present at the Jefferies 2017 Healthcare Conference

SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) --[Lipocine Inc.](http://www.lipocine.com) (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, and Morgan Brown, Executive Vice President and CFO, will provide a corporate overview at the Jefferies 2017 Healthcare Conference, being held June 7-9, 2017 at the Grand Hyatt Hotel in New York City.

## **Presentation Details**

Date: Friday, June 9

Time: 8:00 a.m. Eastern Time

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Lipocine website, [www.lipocine.com](http://www.lipocine.com). Please log on through Lipocine's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on Lipocine's website for 90 days following the presentation.

## **About Lipocine**

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1021, was well tolerated and met the primary efficacy end-point in Phase 3 testing, which utilized 24-hour pharmacokinetic data for dose adjustments, and is currently being studied in two additional Phase 3 clinical trials. LPCN 1111, a novel oral prodrug of testosterone, originated with and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107, the potentially first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit [www.lipocine.com](http://www.lipocine.com).

## **CONTACT:**

Morgan Brown

Executive Vice President & Chief Financial Officer

Phone: (801) 994-7383

[mb@lipocine.com](mailto:mb@lipocine.com)

## **Investors:**

Hans Vitzhum

Phone: (646) 597-6979

[hans@lifesciadvors.com](mailto:hans@lifesciadvors.com)

---

<https://ir.lipocine.com/Lipocine-to-Present-at-the-Jefferies-2017-Healthcare-Conference>